These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19439746)

  • 41. Totect: a new agent for treating anthracycline extravasation.
    Schulmeister L
    Clin J Oncol Nurs; 2007 Jun; 11(3):387-95. PubMed ID: 17623623
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [A case of inflammatory breast cancer treated with preoperative intra-arterial infusion chemotherapy].
    Migita T; Shiiba K; Saito Y; Shibata C; Matsuno S
    Gan To Kagaku Ryoho; 1994 Dec; 21(16):2825-8. PubMed ID: 7993122
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Breast cancer and HIV--the adverse effects chemotherapy.
    García-Tejedor A; Devesa NR; Suárez-Pumariega P; del Barco S; Huerta MV
    Breast J; 2007; 13(6):622-3. PubMed ID: 17983411
    [No Abstract]   [Full Text] [Related]  

  • 44. Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.
    de Azambuja E; Paesmans M; Beauduin M; Vindevoghel A; Cornez N; Finet C; Ries F; Closon-Dejardin MT; Kerger J; Gobert P; Focan C; Tagnon A; Dolci S; Nogaret JM; di Leo A; Piccart-Gebhart MJ
    J Clin Oncol; 2009 Feb; 27(5):720-5. PubMed ID: 19103732
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety of epirubicin adjuvant chemotherapy in a breast cancer patient with chronic renal failure undergoing hemodialytic treatment.
    Gori S; Rulli A; Mosconi AM; Sidoni A; Colozza M; Crinò L
    Tumori; 2006; 92(4):364-5. PubMed ID: 17036534
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epirubicin as adjuvant therapy for breast cancer.
    Suh C
    Cancer Pract; 2001; 9(2):104-6. PubMed ID: 11879287
    [No Abstract]   [Full Text] [Related]  

  • 47. A new conservative approach to extravasation of anthracyclines with dimethylsulfoxide and dexrazoxane.
    Bos AM; van der Graaf WT; Willemse PH
    Acta Oncol; 2001; 40(4):541-2. PubMed ID: 11504316
    [No Abstract]   [Full Text] [Related]  

  • 48. Activity and safety of epirubicin plus paclitaxel in advanced breast cancer.
    Conte PF; Michelotti A; Baldini E; Tibaldi C; DaPrato M; Salvadori B; Giannessi PG; Gentile A; Biadi O; Mariani M
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):28-32. PubMed ID: 8629033
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hypersensitivity reaction during epirubicin infusion in a cat.
    Elliott J
    J Small Anim Pract; 2015 May; 56(5):356. PubMed ID: 25828651
    [No Abstract]   [Full Text] [Related]  

  • 50. Severe adverse reaction to high dose epirubicin and cyclophosphamide for poor prognosis breast cancer.
    Turtle CJ; Keefe DM; Bell D; Wheeler H; Ma DD
    Aust N Z J Med; 1999 Apr; 29(2):275-7. PubMed ID: 10342033
    [No Abstract]   [Full Text] [Related]  

  • 51. Treatment of advanced breast cancer: How much chemotherapy is enough?
    DiPaola RS; Kaufman A; Mikhail MM
    Semin Oncol; 1996 Jun; 23(3):xv-xxii; discussion xxii-xxiv. PubMed ID: 8658211
    [No Abstract]   [Full Text] [Related]  

  • 52. [Acute abdomen in a chemotherapy treated breast cancer patient].
    Trébol J; Duarte M; Gil-López JM; García-Sancho L
    Cir Esp; 2009 Feb; 85(2):115-6. PubMed ID: 19231469
    [No Abstract]   [Full Text] [Related]  

  • 53. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epirubicin for breast cancer during pregnancy: a case report.
    Eedarapalli P; Biswas N; Coleman M
    J Reprod Med; 2007 Aug; 52(8):730-2. PubMed ID: 17879836
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemotherapy and concomitant irradiation in inflammatory breast cancer.
    Tubiana-Mathieu N; Lejeune C; Bonnier P; Genet D; Adjadj DJ; Berda JF; Muracciole X; Delaby F; Clavere P; Benyoub A; Rhein B; Juin B; Piana L
    Anticancer Res; 2001; 21(4B):3061-7. PubMed ID: 11712811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Surgical management after doxorubicin and epirubicin extravasation.
    Fleming A; Butler B; Gault D
    J Hand Surg Br; 1999 Jun; 24(3):390. PubMed ID: 10433467
    [No Abstract]   [Full Text] [Related]  

  • 57. Epirubicin seems to cause venous sclerosis.
    Lennan E; Middleton JM; Luken J
    BMJ; 2005 Oct; 331(7522):966. PubMed ID: 16239707
    [No Abstract]   [Full Text] [Related]  

  • 58. Intractable Crohn's colitis and perianal disease responding to cyclophosphamide and epirubicin.
    Rieger N; Stahl J; Wattchow D
    Dig Dis Sci; 1997 Nov; 42(11):2367-9. PubMed ID: 9398818
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reversible Cardiomyopathy After Epirubicin Administration.
    Koitabashi N; Ohyama Y; Tateno R; Arai M; Rokutanda N; Horiguchi J; Kurabayashi M
    Int Heart J; 2015; 56(4):466-8. PubMed ID: 26104177
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Good clinical and cost outcomes using dexrazoxane to treat accidental epirubicin extravasation.
    Arroyo PA; Perez RU; Feijoo MA; Hernandez MA
    J Cancer Res Ther; 2010; 6(4):573-4. PubMed ID: 21358106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.